Therefore, the number of hospitals as a precaution offered protection from adhesions at Kaiser cut maternity is growing. Best to prevent adhesions by you actively prevents them from the outset. Have they once trained themselves, they can cause complications and must be often surgically removed. This means that the use of an adhesion barrier is already at the first caesarean section”, explains Mr. Sliwinskij, document doctor in the Marienhospital Darmstadt. Scientific studies confirm that the risk of adhesions is reduced significantly: only about seven percent of Cesarean section patients have to use prophylaxis adhesions on without protection it is nearly half. Sliwinskij: adhesion barriers come benefit our patients, that these otherwise under InterGrowth-related pain can suffer. Also complicate existing adhesions reoperation often and can be cause for a subsequent infertility of patients.” How are adhesions? Causes and consequences at the Emperor cut maternity are severed as in all surgical interventions of human tissues.

Adhesions between internal organs and tissues can develop in the course of the body’s own healing process by an excessive wound healing response. The patients do not feel these adhesions initially often. In many cases, they cause no difficulty even years after surgery. If the adhesions but strengthen in the course of time and impede the movement of organs or they constrict even, can prepare the affected huge problems: the complaints range from chronic abdominal pain of intestinal narrowing to an infertility caused by adhesions. Also, adhesions to complications in future emperor cutting childbirth can and do other surgical procedures. Not infrequently they entail operative treatment often only years later. Genzyme provides patients and interested under the Internet address information on the topics of caesarean section and protection from adhesions. In addition also a free service available hotline.

Questions can be via email at. About Genzyme’s Genzyme headquartered in Cambridge, Massachusetts (United States) among the world’s leading biotechnology companies. Since its founding in 1981, Genzyme from a small start-up has developed to one of the most successful companies in the biotechnology sector with more than 12,000 employees in over 40 countries. In the last two decades, Genzyme has brought a variety of breakthrough therapies for some not previously treatable diseases on the market, to help patients in approximately 100 countries. The biotechnology company focused in his Research the area of rare diseases (orphan diseases) and there is the focus on the Lysosomal Storage diseases. In addition, Nephrology and cardiovascular diseases, transplantation medicine and the fields of autoimmune diseases, oncology and malignant thyroid disease and orthopedic applications belong to the research and the field of activity of the company. On the German site in Neu-Isenburg, over 180 employees perceive mainly sales activities and pursue an ethically responsible and service-oriented cooperation with medical professionals and patients.